Democratic Republic of the Congo & United States — Food and Drug Administration

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

United States — Food and Drug Administration: The United States — Food and Drug Administration has approved Inmazeb, a combination of antibodies, to treat Zaire Ebolavirus infection, which Regeneron Pharmaceuticals has donated for potential use in the current outbreak.

Democratic Republic of the Congo: The DRC is the epicenter of the Ebola outbreak, with hundreds of deaths and ongoing transmission.

United States — Food and Drug Administration: The FDA granted EUA for OraSure's test, facilitating rapid deployment during a public health emergency.

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing a severe Ebola outbreak with over 100 deaths, complicated by conflict and challenges in response efforts.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body that Revolution Medicines will seek approval from for its experimental pancreatic cancer drug, daraxonrasib.

Democratic Republic of the Congo: The country is facing an Ebola outbreak, which the CDC is helping to respond to. The confirmation of a permanent director may improve coordination.

United States — Food and Drug Administration: The FDA is mentioned as another agency with a leadership vacancy, but it is not directly involved in this event.